Companies Dominating the Viscosupplementation System Landscape
- Sanofi S.A.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Anika Therapeutics, Inc.
- Seikagaku Corporation
- Smith & Nephew PLC
- Lifecore Biomedical, Inc.
- LG Chem Life Sciences Innovation Center, Inc.
- Fidia Farmaceutici S.p.A.
- F. Hoffmann-La Roche Ltd
- Chugai Pharmaceutical Co., Ltd.
- OrthogenRx, Inc.
Browse Key Market Insights with Data Illustration:
In the News
-
Chugai Pharmaceutical Co., Ltd. has obtained regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) for its osteoporosis treatment Edirol Tablets 0.5 g/0.75 g (generic name: eldecalcitol, hereafter, Edirol Tablet), a vitamin D3 derivative developed by Chugai based on long-standing research into vitamin D.
-
Seikagaku Corporation launched HyLink, an intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis in Taiwan, through TCM Biotech International Corp. The main ingredient of HyLink is a cross-linked hyaluronate hydrogel derived from Seikagaku's crosslinking technology.
